Metalloproteinase-1,Metalloproteinase-7,and p53 Immunoexpression and their Correlation with Clinicopathological Prognostic Factors in Colorectal Adenocarcinoma
Free accessResearch articleFirst published online July, 2009
Metalloproteinase-1,Metalloproteinase-7,and p53 Immunoexpression and their Correlation with Clinicopathological Prognostic Factors in Colorectal Adenocarcinoma
The aim of this study was to analyze the immunoexpression of metalloproteinase-1, metalloproteinase-7, and p53 in colorectal adenocarcinoma, and to correlate this with clinicopathological prognostic factors.
Material and methods
Formalin-fixed paraffin-embedded tumor tissue from 82 patients was analyzed by means of immunohistochemistry, using the streptavidin-biotin method and the tissue microarray technique. Protein tissue expression was correlated with the variables of the degree of cell differentiation, stage, relapse-free survival, recurrence, survival, and specific mortality.
Results
All of the tumors were positive for metalloproteinase-1, while 50 (61%) were positive for metalloproteinase-7, and 32 (39%) were negative for the latter. For p53, 70 (85.4%) of the tumors were positive and 12 (14.6%) were negative. Correlation of the marker expressions separately and in conjunction did not produce any statistically significant data.
Conclusion
The immunoexpression of metalloproteinase-1, metalloproteinase-7, and p53 did not correlate with recurrence, mortality, relapse-free survival, survival, degree of cell differentiation, or staging of colorectal cancer.
GreenleeR.T., MurrayT., BoldenS., WingoP.A.Cancer statistics, 2000. CA Cancer J Clin2000; 50: 7–33.
2.
RicchiP., PignataS., IaffaioliR.V., DanieliB.Cyclo-oxygenase inhibition in colorectal adenomas and cancer. J Clin Gastroenterol2003; 37: 281–7.
3.
ParkinD.M., BrayF., FerlayJ., PisaniP.Global cancer statistics, 2002. CA Cancer J Clin2005; 55: 74–108.
4.
SanbornR., BlankeC.D.Cyclooxygenase-2 inhibition in colorectal cancer: boom or bust?Semin Oncol2005; 32: 69–75.
5.
DuffyM.J., van DalenA., HaglundC.Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer2007; 43: 1348–60.
6.
BarozziC., RavaioliM., D'erricoA.Relevance of biologic markers in colorectal carcinoma: a comparative study of a broad panel. Cancer2002; 94: 647–57.
7.
LabiancaR., La VerdeN., GarassinoM.C.Development and clinical indications of cetuximab. Int J Biol Markers2007; 22(Suppl 4): 40–6.
8.
EngelC.J., BennettS.T., ChambersA.F., DoigG.S., KerkvlietN., O'MalleyF.P.Tumor angiogenesis predicts recurrence in invasive colorectal cancer when controlled for Dukes staging. Am J Surg Pathol1996; 20: 1260–5.
9.
TanigawaN., AmayaH., MatsumuraM.Tumor angiogenesis and mode of metastasis in patients with colorectal cancer. Cancer Res1997; 57: 1043–6.
10.
ChoiH.J., HyunM.S., JungG.J., KimS.S., HongS.H.Tumor angiogenesis as a prognostic predictor in colorectal carcinoma with special reference to mode of metastasis and recurrence. Oncology1998; 55: 575–81.
11.
LiefersG.J., Cleton-JansenA.M., van de VeldeC.J.Micrometastases and survival in stage II colorectal cancer. New Engl J Med1998, 339: 223–8.
12.
BerneyC.R., FisherR.J., YangJ., RussellP.J., CroweP.J.Protein markers in colorectal cancer: predictors of liver metastasis. Ann Surg1999; 230: 179–84.
13.
CascinuS., StaccioliM.P., GaspariniG.Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. Clin Cancer Res2000; 6: 2803–7.
14.
LeeJ.C., ChowN.H., WangS.T., HuangS.M.Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer2000; 36: 748–53.
15.
WuA.W., GuJ., JiJ.F., LiZ.F., XuG.W.Role of COX-2 in carcinogenesis of colorectal cancer and its relationship with tumor biological characteristics and patients' prognosis. World J Gastroenterol2003; 9: 1990–4.
16.
XiongB., SunT.J., HuW.D., ChengF.L., MaoM., ZhouY.F.Expression of cyclooxygenase-2 in colorectal cancer and its clinical significance. World J Gastroenterol2005; 1: 1105–8.
17.
HanahanD., WeinbergR.A.The hallmarks of cancer. Cell2000; 100: 57–70.
18.
ZuckerS., VacircaJ.Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev2004; 23: 101–17.
19.
StamenkovicI.Extracellular matrix remodeling: the role of matrix metalloproteinases. J Pathol2003; 200: 448–64.
20.
Wagenaar-MillerR.A., GordenL., MatrisianL.M.Matrix metalloproteinases in colorectal cancer: is it worth talking about?Cancer Metastasis Rev2004; 23: 119–35.
21.
JucáM., NunesB.L., MenezesH.L., GomesE.G., MatosD.Metaloproteinases 1 e 7 e câncer colorretal. Rev Bras Coloproct2008; 28: 353–62.
22.
GomesE.G.Análise das expressões imunohistoquímicas da metaloproteinase-1, metaloproteinase-7 e do fator de crescimento endotelial vascular no adenocarcinoma colorretal e suas correlações com os fatores prognósticos [tese].São Paulo: Universidade Federal de São Paulo; 2008.
23.
SunamiE., TsunoN., OsadaT.MMP-1 is a prognostic marker for hematogenous metastasis of colorectal cancer. Oncologist2000; 5: 108–14.
24.
NoshoK., YoshidaM., YamamotoH.Association of Ets-related transcriptional factor E1AF expression with overexpression of matrix metalloproteinases, COX-2 and iNOS in the early stage of colorectal carcinogenesis. Carcinogenesis2005; 26: 892–9.
25.
WoessnerJ.F.Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J1991; 5: 2145–54.
26.
HasegawaS., KoshikawaN., MomiyamaN.Matrilysin-specific antisense oligonucleotide inhibits liver metastasis of human colon cancer cells in a nude mouse model. Int J Cancer1998; 76: 812–6.
27.
KioiM., YamamotoK., HigashiS., KoshikawaN., FujitaK., MiyazakiK.Matrilysin (MMP-7) induces homotypic adhesion of human colon cancer cells and enhances their metastatic potential in nude mouse model. Oncogene2003; 22: 8662–70.
28.
WilsonC.L., MatrisianL.M.Matrilysin: an epithelial matrix metalloproteinase with potentially novel functions. Int J Biochem Cell Biol1996; 28: 123–36.
29.
IchikawaY., IshikawaT., MomiyamaN.Detection of regional lymph node metastases in colon cancer using RT-PCR for matrix metalloproteinase 7, matrilysin. Clin Exp Metastasis1998; 16: 3–8.
30.
MasakiT., MatsuokaH., SugiyamaM., AbeN., GotoA., SakamotoA., AtomiY.Matrilysin (MMP-7) as a significant determinant of malignant potential of early invasive colorectal carcinomas. Br J Cancer2001; 84: 1317–21.
31.
YanagisawaN., GeironsonL., Al-SoudW.A., LjunghA.Expression of matrix metalloproteinase-2, -7 and -9 on human colon, liver and bile duct cell lines by enteric and gastric helicobacter species. FEMS Immunol Med Microbiol2005; 44: 197–204.
32.
SoussiT., LegrosY., LubinR., OryK., SchlichtholzB.Multifactorial analysis of p53 alteration in human cancer: a review. Int J Cancer1994; 57: 1–9.
33.
VogelsteinB., LaneD., LevineA.J.Surfing the p53 network. Nature2000; 408: 307–10.
34.
RochaF.T., LourençoL.G., JucáM.J., LealA.T., PazA.M.Expressão da proteína p53 no adenocarcinoma gástrico: correlação clínica, anatomopatológica e significância prognóstica. Rev Col Bras Cir2004; 31: 186–93.
35.
RussoA., BazanV., AgneseV., RodolicoV., GebbiaN.Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies. Ann Oncol2005; 16(Suppl 4): 44–9.
36.
MillsA.A.P53: link to the past, bridge to the future. Genes Dev2005; 19: 2091–9.
37.
HofsethL.J., HussainS.P., HarrisC.C.P53: 25 years after its discovery. Trends Pharmacol Sci2004; 25: 177–81.
FearonE.R., VogelsteinB.A genetic model for colorectal tumorigenesis. Cell1990; 61: 759–67.
45.
MunroA.J., LainS., LaneD.P.P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer2005; 92: 434–44.
46.
LustosaS.A., LogulloA., ArtigianiR., SaadS.S., GoldenbergA., MatosD.Analysis of the correlation between p53 and bcl-2 expression with staging and prognosis of the colorectal adenocarcinoma. Acta Cir Bras2005; 20: 353–7.
47.
DowellS.P., HallP.A.The p53 tumour suppressor gene and tumour prognosis: is there a relationship?J Pathol1995; 177: 221–4.
48.
BrownP.D.Matrix metalloproteinases in gastrointestinal cancer. Gut1998; 43: 161–3.
49.
HilskaM., RobertsP.J., CollanY.U.Prognostic significance of matrix metalloproteinases-1,-2, -7 and 13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer. Int J Cancer2007; 121: 714–23.
50.
BendardafR., BuhmeidaA., RistamäkiR., SyrjänenK., PyrhönenS.MMP-1 (collagenase-1) expression in primary colorectal cancer and its metastases. Scand J Gastroenterol2007; 42: 1473–8.
51.
CohenT., PrusD., ShiaJ.Expression of p53, p27 and Ki-67 in colorectal cancer patients of various ethnic origins: clinical and tissue microarray based analysis. J Surg Oncol2008; 97: 416–22.
52.
LyallM.S., DundasS.R., CurranS., MurrayG.I.Profiling markers of prognosis in colorectal cancer. Clin Cancer Res2006; 12: 1184–91.
53.
BendardafR., LamlumH., VihinenP., RistamäkiR., LaineJ., PyrhönenS.Low-collagenase-1 (MMP-1) and MT1-MMP expression levels are favourable survival markers in advanced colorectal carcinoma. Oncology2003; 65: 337–46.
54.
MurrayG.I., DuncanM.E., O'NeilP., MelvinW.T., FothergillJ.E.Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med1996; 2: 461–2.
55.
BennettM.A., KayE.W., MulcahyH.Ras and p53 in the prediction of survival in Dukes's stage B colorectal carcinoma. Clin Mol Pathol1995, 48: M310–5.
56.
BouzoureneH., GervazP., CerottiniJ.P.p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal Cancer. Eur J Cancer2000; 36: 1008–15.
Hong-ZhiL., Zong-GuangZ., LieY.Clinicopathologic and prognostic significance of MMP-7 (Matrilysin) expression in human rectal cancer. Jpn J Clin Oncol2005; 35: 739–44.
59.
SchwandnerO., SchlampA., BrollR., BruchH.P.Clinicopathologic and prognostic significance of matrix metalloproteinases in rectal cancer. Int J Colorectal Dis2007; 22: 127–36.
60.
van der StappenJ.W., HendriksT., WobbesT.Correlation between collagenolytic activity and grade of histological differentiation in colorectal tumors. Int J Cancer1990; 45: 1071–8.
61.
ShiozawaJ., ItoM., NakayamaT., NakashimaM., KohnoS., SekineI.Expression of matrix metalloproteinase-1 in human colorectal carcinoma. Mod Pathol2000; 13: 925–33.
62.
AdachiY., YamamotoH., ItohF., HinodaY., OkadaY., ImaiK.Contribution of matrilysin (MMP-7) to the metastatic pathway of human colorectal cancers. Gut1999; 45: 252–8.
63.
ZinzindohouéF., LecomteT., FerrazJ.M.Prognostic significance of MMP-1 and MMP-3 functional promoter polymorphisms in colorectal cancer. Clin Cancer Res2005; 11: 594–9.
64.
RoebE., ArndtM., JansenB., SchumpelickV., MaternS.Simultaneous determination of matrix metalloproteinase (MMP)-7, MMP-1, -3, and -13 gene expression by multiplex PCR in colorectal carcinomas. Int J Colorectal Dis2004; 19: 518–24.
65.
HoriuchiS., YamamotoH., MinY., AdachiY., ItohF., ImaiK.Association of ets-related transcriptional factor E1AF expression with tumour progression and overexpression of MMP-1 and matrilysin in human colorectal cancer. J Pathol2003; 200: 568–76.
66.
BakerE.A., BerginF.G., LeaperD.J.Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging. Br J Surg2000; 87: 1215–21.
67.
GeorgievaM., KrastevaM., AngelovaE.Analysis of the K-ras/B-raf/Erk signal cascade, p53 and CMAP as markers for tumor progression in colorectal cancer patients. Oncol Rep2008; 20: 2–11.
68.
LustosaS.A.O valor prognóstico e a correlação histopatológica das proteínas p53 e Bcl-2 em doentes portadores de adenocarcinoma colorretal, submetidos ao tratamento cirúrgico [tese].São Paulo: Universidade Federal de São Paulo; 2003.
69.
ParadisoA., VolpeS., IacobacciA.; Italian Network for Quality Assessment of Tumor Biomarkers. Quality control for biomarker determination in oncology: the experience of the Italian Network for Quality Assessment of Tumor Biomarkers (INQAT). Int J Biol Markers2002; 17: 201–14.
